Re: Resverlogix Announces Publication on Apabetalone in Clinical Epigenetics
posted on
Jul 15, 2019 07:12PM
Your numbers make good sense relative to what has been revealed at conferences up through early this year. So somewhere around 5% annual MACE (3 pt) for the trial.
That seems like a nice low number......
(I know there are a lot of caveats...)